Menu
← Oncology Approval Tracker
FDA DECISION ·
Ojemda
tovorafenib · Day One Biopharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma and a BRAF fusion, rearrangement or V600 mutation.
LAMPGEN ANALYSIS
Why it matters
The type II RAF inhibitor reaches pediatric gliomas with qualifying fusions as well as V600 variants.
What research teams should watch
Capture the precise BRAF alteration and prior therapy; use age-appropriate administration training and consistent MRI assessments.
PRIMARY RECORDS